GlaxoSmithKline PLC’s transformational deal withNovartis AGentails GSK selling its cancer business, forming a consumer-health venture with the Swiss drug maker, and buying most of Novartis’ vaccines business in a complex transaction that effectively ends the British group’s ambitions to be a world leader in oncology.
GSK’s three-part transaction with Novartis, announced April 22, will give it a controlling 63.5% in the proposed GSK/ Novartis consumer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?